| Name | Title | Contact Details |
|---|
Grand Valley Technology Services is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
APA Service Center is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clean Plates Omnimedia LLC is a premier media company focused on the new health and wellness food culture, with products that include digital, print and social media, as well as mobile apps. Begun in 2009 by Jared Koch–a certified nutritionist from the Institute for Integrative Nutrition and the Global Institute for Alternative Medicine—Clean Plates provides an integrative approach through food, sustainability, and wellness to optimize your health and happiness, thereby helping you perform at your peak—whether on the go, in the kitchen or dining out.
A regional leader in hospice and palliative care, Agape Care Group proudly serves more than 1,500 patients across South Carolina and Georgia. Agape Care South Carolina serves all 46 counties in the state and is also the only statewide palliative and hospice provider with a dedicated pediatric team through our Hands of Hope program. And in Georgia, we deliver care to 12 counties through our Augusta location, the cornerstone of the network we’re continuing to build. At Agape Care Group, we pride ourselves on our goal-oriented culture, dynamic leadership, and team-first attitude, and we’re committed to creating an inclusive, respectful workplace that reflects our core values. Our 900-plus employees are the heart of what we do, which is why we provide them with the resources and continuing education they need to excel. We strive to be an employer of choice in the health care industry, and we’re dedicated to building and maintaining an encouraging environment for our team members.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.